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ABSTRACT 
Adrenocortical carcinoma (ACC) is an aggressive cancer with poor long-term survival. 
Apart from radical surgery, there is a reduced range of therapeutic possibilities and 
mitotane remains the cornerstone of the treatment in adjuvant and palliative setting. 
Even though many decades after its introduction in clinical practice, there are still many 
uncertainties surrounding the applied use and the actual benefit of this old drug.  
Recent ACC guidelines suggest adjuvant mitotane for patients at high risk of recurrence, 
and chemotherapy plus mitotane in metastatic disease, moreover the use of mitotane 
monotherapy has been proposed in a subset of patients. 
When using mitotane, physicians have to consider and manage its potential toxicity and 
endocrine effects that need a complex supporting therapy. 
 
BACKGROUND 
Adrenocortical cancer (ACC) is a rare and aggressive cancer, with an overall 5-year 
survival rate of 16% - 47% (1). Patient outcome is mainly influenced by completeness of 
surgical removal and tumor stage at diagnosis (2). However, prognosis is not uniform 
and survival at any stage may vary depending on clinical, pathological and molecular 
factors that have been partially elucidated (3). 
Development of treatment options beyond surgery has been limited. Surgery, however, 
may cure only a few patients, while most of them will suffer recurrence and tumor 
progression leading to death. Therefore, there is an urgent need to develop effective 
medical treatments to improve patient outcome. Up to now, no personalized approach 
has been developed, and no simple targetable molecular event has been identified from 
preclinical studies (1) (4) (5).  
To underline the low level of evidence on medical treatment of ACC it is enough to 
remember that only two randomized controlled trials on advanced ACC have been 
conducted (6) (7), while no randomized study is available on adjuvant treatments. 
In this unpleasant scenario, mitotane remains the cornerstone of ACC treatment being 
currently used both in adjuvant and palliative setting. However, more than 50 years after 
its introduction in clinical practice, there are still many uncertainties surrounding the use 
of this old drug. 
The scope of this work is to present a concise review of recent advances in the use of 
mitotane. 
MITOTANE FOR ADJUVANT TREATMENT 
Given that ACC has a strong propensity to recur after surgery (8) and that tumor 
recurrence is also frequently observed after microscopically radical (R0) operations done 
by skilled surgeons (9), implementation of adjuvant treatments in clinical practice 
appears as a sound strategy (10). The adjuvant treatment mostly employed in clinics has 
been the administration of mitotane, although there is an ongoing debate on its actual 
efficacy. Lacking results from randomized controlled trials, the best evidence in favor of 
adjuvant mitotane in ACC patients following radical surgery comes from a large 
retrospective case-control study by our group. The study showed that patients treated 
with adjuvant mitotane had a significantly survival advantage compared with that of 
patients left untreated following surgery (11). Strengths of the study are its statistical 
power and that treatment assignment was center-specific (i.e. all patients of a given center 
were treated or not) and not based on patient characteristics, thus resulting in the 
inclusion of well-matched control groups. The retrospective nature of the study, however, 
does not allow concluding definitively that adjuvant mitotane treatment is beneficial. 
An uneven patient selection confounds the interpretation of the study outcomes, as 
exemplified by a retrospective analysis of 207 ACC patients claiming that adjuvant 
mitotane treatment was associated with reduced recurrence-free survival (RFS). In that 
study, however, 28% of patients treated with adjuvant mitotane had metastatic ACC at 
presentation compared to 9% of untreated patients. Therefore, the study suffers from a 
confounding by indication since the mitotane-treated patients had a far higher risk of 
recurrence at baseline than untreated patients, a difference that cannot be fully adjusted 
for in multivariate analysis (12). 
Our group has updated the follow-up of the cohorts of patients included in the 2007 study 
(11) with almost 10 years of additional observation, confirming that adjuvant mitotane 
treatment is associated with a significant benefit in terms of RFS regardless of the 
hormone secretory status (13). Median RFS was 42 months in the adjuvant group 
compared with 17 months in control group 1 (p<0.001) and 26 months control group 2 
(p<0.005) (13). Mitotane-treated patients had a significant benefit in overall survival (OS) 
in comparison with the control group 1, while the difference in OS just failed to reach 
statistical significance with the control group 2 (13). In this study, landmark analysis was 
employed to circumvent the immortal-time bias that is a common confounder of this type 
of studies.  
Efficacy of adjuvant mitotane treatment has been the subject of two recent meta-analyses 
that were able to retrieve only 6 and 5 studies, respectively, fulfilling the quality criteria of 
sufficient patient number, presence of a concomitant control group of untreated patients 
and reporting of baseline patient characteristics. Due to the variable inclusion criteria and 
different study procedures, a remarkable heterogeneity between studies was apparent in 
both meta-analyses that were not able to identify predictors of response to adjuvant 
mitotane (14) (15). Both meta-analyses, however, concluded that adjuvant mitotane was 
associated with a significant prolongation of OS, while the increment in RFS resulted 
statistically significant only in one (15).  
The European Society of Endocrinology - ENSAT guidelines on the management of 
ACC suggest adjuvant mitotane treatment for patients at high risk of recurrence 
following complete tumor extirpation, although recognizing the low level of evidence of 
this recommendation (Figure 1). Adjuvant mitotane remains an option to be discussed on 
individual basis for patients at low risk of recurrence (14). This subset of patients is the 
target of the randomized controlled study ADIUVO (www.epiclin.it/adiuvo) whose 
results are expected in the next year. 
We have recently reviewed our experience with adjuvant mitotane treatment in non-
metastatic ACC patients following complete tumor resection (16). We did a retrospective 
analysis of 152 patients who have not been included in previous studies. Of those, 100 
patients underwent adjuvant mitotane therapy after initial surgery (mitotane group) and 
52 were not treated with any adjuvant treatment following surgery (control group). The 
median RFS was 36.5 months (4-199) in the mitotane group and 21 months (4-180) in 
the control group (p<0.001). The difference in OS was not significantly different between 
treated and untreated patients; however, in the group of patients with either stage III 
ACC or ki67 index >10% adjuvant mitotane was associated with a significant 
prolongation of RFS (p=0.014) (Figure 2). Interestingly, hormone-secreting ACC showed 
a higher ki67 index and this may explain why hormone secretion was a worse prognostic 
factor, confirming previous observations (17). In our experience, a low-dose mitotane 
regimen had acceptable toxicity and most patients were able to tolerate long-term 
treatment. Therefore, this study is the first to support, although on a retrospective basis, 
the current recommendation of adjuvant mitotane therapy in ACC patients at high risk of 
recurrence following radical surgery.  
 
MITOTANE FOR TREATMENT OF ADVANCED DISEASE  
The management of ACC patients with metastatic disease is challenging and the 
prognosis is generally poor, since most patients are doomed to die of disease progression 
within 1-2 years. However, ACC is a heterogeneous disease and a subset of patients 
bearing less aggressive tumors may experience quite prolonged survival. Several 
prognostic factors such as time since initial surgery, presence of distant metastases, 
number of metastatic lesions and number of organs involved, and high tumor grade have 
been found to predict survival in patients with metastatic ACC (18) (19). Moreover, 
studies indicated that overt cortisol excess is associated with a detrimental prognosis due 
to the associated morbidity (20) (21). 
Treatment of advanced/metastatic patients may include as therapeutic tools loco-
regional approaches, such as surgery, radiofrequency ablation and chemoembolization, 
in patients with slowly progressive disease and low metastatic burden (22) (23) (24). 
Loco-regional measures may synergize with systemic therapies to attain long-lasting 
tumor control in patients with less aggressive ACC. In presence of low-grade tumors with 
limited metastatic burden, therefore, it is reasonable to offer single-agent mitotane as a 
systemic option (14). Early studies assessing the efficacy of single-agent mitotane 
reported a rate of objective tumor responses between 13% and 31% (25) (26) (27). 
However, most of the responses were of limited duration and complete responses were 
rarely observed. The outcome of these studies raised the concept of a “therapeutic range” 
of plasma mitotane concentrations that should be targeted in any patient with 
advanced/metastatic ACC. As a matter of fact, disease responses were mainly confined 
in patients attaining plasma mitotane concentration between 14 and 20 mg/L (25) (26) 
(27).  
This concept has been validated more recently in a retrospective series of 127 patients 
receiving mitotane monotherapy for advanced ACC (28). In this study, the patients who 
reached a peak mitotane concentration >14 mg/L had longer RFS and OS than patients 
who did not. Interestingly, also the rate of objective responses was higher in patients with 
mitotane concentrations at target, even if some responses were observed with lower 
levels. Overall, a complete response was observed in 2.3% of patients, a partial response 
in 18.1%, and disease stabilization in 25.2%, respectively. Interestingly, objective tumor 
responses were as high as 30% in patients with either low tumor burden (<10 tumour 
lesions) or longer RFS after primary surgery (≥360 days) (Figure 3). Although the OS 
was quite limited, being 18.5 months, mitotane monotherapy was able to attain long-
lasting tumor control in a number of patients (28). Therefore, the study supports the 
concept that mitotane is a slow-acting drug, and that mitotane monotherapy is indicated 
in the management of patients with a low tumor burden and/or more indolent disease. 
Conversely, chemotherapy plus mitotane are currently recommended for patients with 
aggressive disease and multiple metastases (14). 
Very recently, the outcome of single-agent monotherapy has been reported in 36 patients 
with metastatic ACC treated at a single center. In this retrospective series, most patients 
progressed under treatment but a remarkable 8% complete response rate was observed. 
The responding patients had non-functioning tumors with a low-volume disease (29). 
Although on a limited patient cohort, the study confirms that mitotane monotherapy 
may be effective in selected ACC patients. 
Owing to the latency of action of mitotane associated to the time needed to reach the 
therapeutic target, it is unclear how long clinicians should wait to assess the efficacy, or 
the lack of, of mitotane therapy. As a consequence, mitotane is continued almost 
indefinitely in many patients with advanced ACC lacking clear rules for its 
discontinuation. A recent study aimed to clarify this issue, evaluating the time until a 
partial response was attained in patients with metastatic ACC (30). A cohort of 68 
patients who survived more than 24 months after diagnosis of stage IV ACC was 
retrospectively analyzed, including 57 patients treated with mitotane monotherapy and 
the remainders with mitotane associated to chemotherapy. In this selected cohort of long-
term survivors, almost all objective responses were observed within 12 months from start 
of mitotane and this finding suggests that mitotane may be discontinued after that time if 
ACC continues to progress. The value of the therapeutic range was reaffirmed, since 
responses were more frequently and rapidly observed in patients attaining mitotane 
concentrations >14 mg/L. The association between response and target mitotane 
concentrations was less apparent when mitotane was used with chemotherapy (30).  
ENDOCRINE EFFECTS OF MITOTANE  
It is held that mitotane has a plethora of effects on the endocrine system; thus, the drug 
can be regarded as an endocrine disruptor (31). In addition to its inhibitory effect on 
adrenal steroidogenesis, mitotane affects also testosterone synthesis, pituitary function 
(32) (33) (34) (35) and has an inherent estrogenic effect that has been recently 
demonstrated in vivo, in a mitotane-treated child who developed a peripheral precocious 
puberty (31). 
The effects of mitotane on the hypothalamic-pituitary-adrenal axis were thoroughly 
investigated in a prospective cohort of 16 ACC patients treated following radical tumor 
resection (36). The study showed that chronic mitotane treatment led to adrenal 
insufficiency in most but not all patients, despite that therapeutic concentrations were 
reached in 50% of cases. Interestingly, ACTH levels were elevated in most but not all 
patients, and the ACTH response to CRH was lower than in a cohort of patients with 
Addison’s disease (36). This finding may result from an inhibitory effect of mitotane on 
pituitary ACTH, as previously demonstrated in vitro (33).  
The study was unable to find biomarkers that may help to guide hormone replacement in 
mitotane-treated patients, which is not an easy task due to the increased metabolic 
clearance of exogenous steroids on mitotane treatment (37). This implies that doses of 
cortisone acetate as high as 50-100 mg daily (36), or hydrocortisone 40-80 mg daily (38), 
are needed in ACC patients on mitotane. In an attempt to simplify glucocorticoid 
replacement, ACC patients on mitotane were switched from immediate to modified 
release hydrocortisone. However, the use of equivalent doses of modified release 
hydrocortisone resulted in insufficient hydrocortisone coverage; thus, the new 
formulation of hydrocortisone cannot be recommended for mitotane-induced adrenal 
insufficiency (38). 
Mitotane is able to alter testosterone levels trough a complex effect including a sharp 
rise in the levels of sex hormone binding protein (SHBP) and a delayed inhibition of 
testosterone synthesis and secretion by the testis. As a consequence, levels of total 
testosterone may actually rise in a first phase, or remain normal, but free testosterone 
(the bioactive fraction) is reduced causing sexual dysfunction in about 30% of men on 
longstanding treatment. Sex steroid replacement may become necessary to treat male 
hypogonadism but can worsen gynecomastia, to which concurs the intrinsic estrogenic 
effect of mitotane (32). 
Mitotane interferes with thyroid function and hypothyroidism becomes apparent early 
in the course of treatment in about half of treated patients. Mitotane administration is 
associated with low fT4 levels without a compensatory rise in TSH, a finding that 
recalls central hypothyroidism due to the inhibitory effect of mitotane on the synthesis 
and secretion of TSH (32,35).   
Mitotane treatment is also associated with increasing levels of LDL, HDL 
cholesterol, and triglycerides (32). However, the value of introducing statins remains 
uncertain and the decision to use anti-lipid drugs should be carefully though 
considering the cardiovascular risk and life expectancy of the treated patients (10, 14). 
Clinicians should avoid in mitotane-treated patients drugs metabolized by citocrome 
P450 subtype 3A4, such as some statins, anti-hypertensive drugs, hormones, 
benzodiazepines, because of the expected reduction in drug concentration and effect 
due to this pharmacologic interaction (14). 
 
 
CONCLUSION 
Novel data on the efficacy of single-agent mitotane treatment, either as adjuvant or 
palliative measure, have been published that may help in selecting patients who may 
benefit from treatment. However, the level of evidence remains low in the absence of 
prospective studies that are urgently needed to make significant advances in the 
treatment of ACC patients. 
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ANNOTATIONS TO REFERENCES 
13. ** An updated follow-up of the 3 patient cohorts (1 mitotane-treated and 2 
concomitant untreated groups) reported in 2007, now with 9 additional years of 
observation and better statistics (landmark analysis) confirming the benefit of adjuvant 
mitotane treatment on RFS. 
14. ** The first comprehensive guidelines on the management of ACC patients providing 
clinically useful guidance for treatment of this rare tumor. 
15. * A meta-analysis of the available evidence on adjuvant mitotane therapy. 
16. ** The first evidence, still retrospective, that adjuvant mitotane is beneficial in 
patients at high risk of recurrence (i.e. patients with stage III ACC and/or ki67 index 
>10%). 
27. ** The largest study on mitotane monotherapy for advanced ACC showing the 
efficacy of treatment and identifying predictive factors of response. 
28. * A small sized study on mitotane monotherapy for advanced ACC showing the 
efficacy of treatment. 
29. * A study aiming to asses the correct timing of mitotane discontinuation and the 
relation between activity and target plasma concentrations of the drug. 
30. * A case-report of a child with ACC treated with mitotane that illustrates the multiple 
effects of the drug on the endocrine system. 
35. * A detailed assessment of the multiple effects of mitotane on the HPA axis of ACC 
patients on chronic adjuvant treatment. Mitotane affects also pituiatry ACTH secretion. 
37. * Modified release hydrocortisone does not work as well as immediate release 
hydrocortisone as repleacement in mitotane-treated patients. 
 
LEGENDS TO FIGURES 
Figure 1. Treatment flow-chart of localized adrenocortical carcinoma (Modified from 
Fig. 3 of Fassnacht et al., 2018). 
Figure 2. Recurrence-free survival of patients at high risk of recurrence (stage III ACC or 
ki67>10%) treated with mitotane (solid line) or non-treated (dotted-line) following 
radical surgery. 
Figure 3. Influence of the timing of mitotane initiation and tumour burden on overall 
survival (Modified from Fig. 2 of Megerle et al., 2018) 
 
ACC amenable to complete resection
Follow-up every 3 months:
imaging and tumor markers
Tumor free
Adjuvant mitotane
Low/intermediate risk High risk
ENSAT I+II and Ki67 ≤10%
Rx or R1 resection2
Consider mitotane 
Adjuvant mitotane
+ consider radiation therapy
Recurrence
complete resection (R0) 
ENSAT III+IV or Ki67 >10%
DFI < 6 months or not resectable
See figure 4
DFI > 12 months + 
completely resectable
S
 
u
 
r
 
g
 
e
 
r
 
y
Completed  Censored
 Mitotane
 Non treated
0 20 40 60 80 100 120 140 160 180 200 220
Months
-0,1
0,0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1,0
R
ec
ur
re
nc
e-
fre
e 
S
ur
vi
va
l

